Clinical Trial Update: Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating safety and efficacy of AS101 1% oral solution in neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• AS101 1% oral solution (AS101)

Snippet

Sponsor: Feramda | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED